Growth Differentiation Factor 15 (GDF15) (N-Term) antibody (Biotin)

Antigen: Growth Differentiation Factor 15 (GDF15)

Synonyms: GDF15, PDF, MIC1, PLAB, MIC-1, NAG-1, PTGFB, GDF-15, SBF

Binding Site: N-Term

Clonality: Polyclonal

Host: Rabbit

Reactivity: Human

Conjugate: Biotin

Application: Flow Cytometry (FACS), Fluorescence Microscopy (FM)

Catalog no.: ABIN1043923

Additional Information

Alternative name: Nag-1

Gene ID: 9518

NCBI Acession: Q99988.3

UniProt: Q99988

Immunogen: This affinity purified antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the amino terminal end of human NAG-1 protein.  A residue of cysteine was added to facilitate coupling to KLH.
Immunogen Type: Peptide

Format: Lyophilized

Reconstitution: Reconstitution Buffer: Restore with deionized water (or equivalent), Reconstitution Volume: 100 µL

Isotype: IgG

Description: This affinity purified antibody is suitable for ELISA and western blotting of human NAG-1 protein.  For detection of NAG-1 in human serum, a sandwich ELISA is suggested using this antibody in combination with anti-NAG-1/GDF15 C-terminal specific antibodies.  This antibody is useful in dual antibody immunometric assays (EIA). Specific conditions for reactivity should be optimized by the end user.  Expect bands in western blots of approximately 14 kDa in size corresponding to NAG-1 monomer using the appropriate cell lysate or extract.

Synonyms: NAG-1, GDF15, MIC-1, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, prostate-derived factor.

Characteristics: Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.

Specificity: This product was affinity purified from monospecific antiserum by immunoaffinity chromatography.  This antibody specifically reacts with the amino terminal end of human NAG-1 protein from human tissues.  A BLAST analysis was used to suggest partial reactivity with NAG-1 from chimpanzee and macaque based on a 92% homology.  Multimeric forms of NAG-1 may be detected.  Cross-reactivity with NAG-1 from other sources has not been determined.

Comments:

Gene Name: GDF15

Application Details

Purification: affinity purified

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2, 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free

Preservative: 0.01% (w/v) Sodium Azide

Storage Comment: Store vial at 4° C prior to restoration.   For extended storage aliquot contents and freeze at -20° C or below.  Avoid cycles of freezing and thawing.  Centrifuge product if not completely clear after standing at room temperature.  This product is stable for several weeks at 4° C as an undiluted liquid.  Dilute only prior to immediate use. 

Expiry Date: Expiration date is one (1) year from date of opening.

Restrictions: For Research Use only

Publications

Product: Baek, Eling: "Changes in gene expression contribute to cancer prevention by COX inhibitors." in: Progress in lipid research, Vol. 45, Issue 1, pp. 1-16, 2006 (PubMed).